Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes (SEMA-CKM)

Real-world Canadian Retrospective Study Evaluating Longitudinal SEMAglutide Use on Cardio-Kidney-Metabolic Outcomes

The goal of this study is to better understand the real-world effectiveness of semaglutide use on cardio-kidney-metabolic outcomes among adults with T2D and adults with obesity (without diabetes mellitus). This is a retrospective longitudinal analysis using the LMC Diabetes Registry. The primary outcome of the study is to evaluate the change in HbA1c between baseline to 3 years of follow-up among adults with T2D who initiated semaglutide compared to adults with T2D who initiated other AHAs, including sulfonylurea, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors.

Study Overview

• Status: Not yet recruiting
• Conditions: Type 2 Diabetes; Diabetes (DM); Obesity (Disorder)
• Intervention / Treatment: Drug: Semaglutide (SEMA)

• Study Type: Observational
• Enrollment (Estimated): 400

Contacts and Locations

• Study Contact: Name: Lisa Chu, PhD; Phone Number: (416) 645-2929; Email: lisa.chu@lmc.ca
• Study Contact Backup: Name: giovana Romero, Msc; Phone Number: (416) 645-2929; Email: giovana.romero@lmc.ca

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

The study populations will include adults with T2D prescribed semaglutide (T2D sema cohort) or other AHA (T2D other AHA cohort) including sulfonylurea, DPP4i, and/or SGLT2i, or adults with obesity, defined as BMI equal or greater 27 kg/m2, prescribed semaglutide (obesity sema cohort), who attend an LMC Diabetes & Endocrinology clinic

Description

Inclusion Criteria:

T2D Cohort:

• A clinical diagnosis of T2D ≥ 1 year
• HbA1c ≥ 6.5% (pre-index date)
• Initiated semaglutide or other AHA(s) before January 1st, 2023*
• Seen by an LMC endocrinologist in the last 18 months as of the query date
• ≥ one HbA1c value up to 6 months (+ 90 days) prior to index date
• Informed data consent for their medical record data to be used for research purposes

Obesity Cohort:

• 18 years or older
• BMI ≥ 27 kg/m2
• HbA1c < 6.5% (pre-index date)
• Initiated semaglutide before January 1st, 2023*
• Seen by an LMC endocrinologist in the last 18 months as of the query date
• ≥ one HbA1c value up to 6 months (± 90 days) prior to index date
• Informed data consent for their medical record data to be used for research purposes

Exclusion Criteria:

• Clinical diagnosis of type 1 diabetes/latent autoimmune diabetes in adults (LADA)
• Clinical diagnosis of T2D (obesity cohort only)
• Are pregnant at the time of semaglutide or other AHA initiation or became pregnant during follow-up period
• Documented history or family history of medullary thyroid carcinoma
• Participation in a research study with an Investigational Product
• eGFR < 15 mL/min/1.73m2 at index date
• Use of non-semaglutide GLP-1-based medication for more than 6 months after the index date (T2D sema cohort and obesity sema cohort)
• Use of other AHA for more than 6 months after the index date within the first year of semaglutide use (T2D sema cohort and obesity sema cohort)

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
T2D Semaglutide Cohort; Adults with T2D prescribed semaglutide	Drug: Semaglutide (SEMA); participants who initiate semaglutide
T2D other AHA cohort; Adults with T2D prescribed antihyperglycemic medication beside semaglutide including sulfonylurea, DPP4i, and/or SGLT2i
Obesity Semaglutide Cohort; Adults with obesity, defined as BMI equal or greater than 27 kg/m2, prescribed semaglutide	Drug: Semaglutide (SEMA); participants who initiate semaglutide

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in HbA1c- 3 Years	The primary outcome measure is investigating the change in HbA1c from baseline to 3 years (± 90 days) among adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs	Baseline to 3 Years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in HbA1c- 1 Year	Comparing the change in HbA1c between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts	Baseline to 1 year
Change in HbA1c- 2 Years	Comparing the change in HbA1c between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 2 Years
Proportion of individuals who achieve HbA1c ≤ 7.0% - 1 Year	comparing the proportion of individuals who achieve HbA1c ≤ 7.0% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts	Baseline to 1 Year
Proportion of individuals who achieve HbA1c ≤ 7.0%- 2 Years	comparing the proportion of individuals who achieve HbA1c ≤ 7.0% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 2 Years
Proportion of individuals who achieve HbA1c ≤ 7.0% - 3 Years	comparing the proportion of individuals who achieve HbA1c ≤ 7.0% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 3 Years
Change in body weight- 1 Year	comparing the change in body weight (kg) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts	Baseline to 1 Year
Change in body weight- 2 Years	comparing the change in body weight (kg) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 2 Years
Change in body weight- 3 Years	comparing the change in body weight (kg) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 3 Years
Percent body weight loss ≥ 5% - 1 Year	comparing the percent body weight loss ≥ 5% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts	Baseline to 1 Year
Percent body weight loss ≥ 5% - 2 Years	comparing the percent body weight loss ≥ 5% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 2 Years
Percent body weight loss ≥ 5% - 3 Years	comparing the percent body weight loss ≥ 5% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 3 Years
Percent body weight loss ≥ 10% - 1 Year	comparing the percent body weight loss ≥ 10% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts	Baseline to 1 Year
Percent body weight loss ≥ 10% - 2 Years	comparing the percent body weight loss ≥ 10% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 2 Years
Percent body weight loss ≥ 10% - 3 Years	comparing the percent body weight loss ≥ 10% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 3 Years
Percent body weight loss ≥ 15% - 1 Year	comparing the percent body weight loss ≥ 15% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts	Baseline to 1 Year
Percent body weight loss ≥ 15%- 2 Years	comparing the percent body weight loss ≥ 15% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 2 Years
Percent body weight loss ≥ 15%- 3 Years	comparing the percent body weight loss ≥ 15% between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 3 Years
Change in BMI- 1 Year	comparing the change in BMI (kg/m^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts	Baseline to 1 Year
Change in BMI- 2 Years	comparing the change in BMI (kg/m^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 2 Years
Change in BMI- 3 Years	comparing the change in BMI (kg/m^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 3 Years
Change in Waist Circumference- 1 Year	comparing the change in waist circumference (cm) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts	Baseline to 1 Year
Change in Waist Circumference- 2 Years	comparing the change in waist circumference (cm) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 2 Years
Change in Waist Circumference- 3 Years	comparing the change in waist circumference (cm) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 3 Years
Change in Blood Pressure- 1 Year	comparing the change in blood pressure between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts	Baseline to 1 Year
Change in Blood Pressure- 2 Years	comparing the change in blood pressure between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 2 Years
Change in Blood Pressure- 3 Years	comparing the change in blood pressure between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 year in the kidney, liver and cardiovascular sub-cohorts	Baseline to 3 Years
Change in eGFR- 1 Year	comparing the change in eGFR (ml/min1.73m^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts	Baseline to 1 Year
Change in eGFR- 2 Years	comparing the change in eGFR (ml/min1.73m^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 2 Years
Change in eGFR- 3 Years	comparing the change in eGFR (ml/min1.73m^2) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 3 Years
Proportion of individuals with ≥ 50% decline in eGFR- 1 Year	comparing the proportion of individuals with ≥ 50% decline in eGFR between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts	Baseline to 1 Year
Proportion of individuals with ≥ 50% decline in eGFR- 2 Years	comparing the proportion of individuals with ≥ 50% decline in eGFR between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 2 Years
Proportion of individuals with ≥ 50% decline in eGFR- 3 Years	comparing the proportion of individuals with ≥ 50% decline in eGFR between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 3 Years
Change in uACR- 1 year	comparing the change in uACR (mg/mmol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts	Baseline to 1 Year
Change in uACR- 2 years	comparing the change in uACR (mg/mmol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 2 Years
Change in uACR- 3 Years	comparing the change in uACR (mg/mmol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 3 Years
Change in ALT- 1 Year	comparing the change in ALT (U/L) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts	Baseline to 1 Year
Change in ALT- 2 Years	comparing the change in ALT (U/L) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 2 Years
Change in ALT- 3 Years	comparing the change in ALT (U/L) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 3 Years
Change in Lipids- 1 Year	comparing the change in lipids (triglycerides, low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], total cholesterol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts	Baseline to 1 Year
Change in Lipids- 2 Years	comparing the change in lipids (triglycerides, low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], total cholesterol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 2 Years
Change in Lipids- 3 Years	comparing the change in lipids (triglycerides, low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], total cholesterol) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 3 Years
Change in number of non-insulin AHAs, excluding GLP-1 based therapies- 1 Year	comparing the change in the number of non-insulin AHAs, excluding GLP-1 based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts	Baseline to 1 Year
Change in number of non-insulin AHAs, excluding GLP-1 based therapies- 2 Years	comparing the change in the number of non-insulin AHAs, excluding GLP-1 based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 2 Years
Change in number of non-insulin AHAs, excluding GLP-1 based therapies- 3 Years	comparing the change in the number of non-insulin AHAs, excluding GLP-1 based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 3 Years
Number of non-semaglutide GLP-1-based therapies- 1 Year	comparing the number of non-semaglutide GLP-1-based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts	Baseline to 1 Year
Number of non-semaglutide GLP-1-based therapies- 2 Years	comparing the number of non-semaglutide GLP-1-based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 2 Years
Number of non-semaglutide GLP-1-based therapies- 3 Years	comparing the number of non-semaglutide GLP-1-based therapies between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 3 Years
Change in insulin use- 1 Year	comparing the change in insulin use (none, basal only, basal-bolus) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts	Baseline to 1 Year
Change in Insulin- 2 Years	comparing the change in insulin use (none, basal only, basal-bolus) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 2 Years
Change in Insulin- 3 Years	comparing the change in insulin use (none, basal only, basal-bolus) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 3 Years
Change in TDD of insulin- 1 Year	comparing the change in TTD of insulin (U) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 1 year in the kidney, liver and cardiovascular sub-cohorts	Baseline to 1 Year
Change in TDD of insulin- 2 Years	comparing the change in TTD of insulin (U) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 2 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 2 Years
Change in TDD of insulin- 3 Years	comparing the change in TTD of insulin (U) between adults with T2D who initiated semaglutide compared with adults with T2D who initiated other AHAs at 3 years in the kidney, liver and cardiovascular sub-cohorts	Baseline to 3 Years
Incidence of non-acetylsalicylic acid antiplatelet use	comparing the incidence of non-acetylsalicylic acid antiplatelet use between adults with T2D treated with 1 or more years of semaglutide and adults with T2D treated with 1 or more years of other AHAs in the cardiovascular sub-cohort	Baseline to Endpoint
Percent body weight loss ≥ 5%	Comparing the percent body weight loss ≥ 5% in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)	Baseline to 1 Year
Percent body weight loss ≥ 10%	Comparing the percent body weight loss ≥ 10% in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)	Baseline to 1 Year
Percent body weight loss ≥ 15%	Comparing the percent body weight loss ≥ 15% in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)	Baseline to 1 Year
Body Weight	Comparing body weight (kg) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)	Baseline to 1 Year
BMI	Comparing BMI (km/m^2) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)	Baseline to 1 Year
Waist Circumference	Comparing the waist circumference (cm) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)	Baseline to 1 Year
HbA1c	Comparing HbA1c (%) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)	Baseline to 1 Year
Percent of new onset pre-diabetes	Comparing the percent of new onset pre-diabetes (%) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)	Baseline to 1 Year
Percent of new onset T2D	Comparing the percent of new onset T2D (%) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)	Baseline to 1 Year
Blood Pressure	Comparing blood pressure in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)	Baseline to 1 Year
eGFR	Comparing eGFR (ml/min1.73m^2) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)	Baseline to 1 year
uACR	Comparing uACR (mg/mmol) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)	Baseline to 1 Year
ALT	Comparing ALT (U/L) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)	Baseline to 1 Year
Lipids	Comparing lipids (triglycerides, LDL-C, HDL-C , total cholesterol) in the cohort of adults with obesity treated with semaglutide from the index date to 1 year of follow-up (± 90 days)	Baseline to 1 Year

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
HbA1c	Comparing HbA1c between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups	Baseline to Endpoint (3 Years)
Proportion of individuals who achieve HbA1c ≤ 7.0%	Comparing the proportion of individuals who achieve HbA1c ≤ 7.0% between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups	Baseline to Endpoint (3 Years)
Body Weight	Comparing body weight (kg) between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups	Baseline to Endpoint (3 Years)
Percent body weight loss ≥ 5%	Comparing percent body weight loss ≥ 5% between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups	Baseline to Endpoint (3 Years)
Percent body weight loss ≥ 10%	Comparing percent body weight loss ≥ 10% between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups	Baseline to Endpoint (3 Years)
Percent body weight loss ≥ 15%	Comparing percent body weight loss ≥ 15% between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups	Baseline to Endpoint (3 Years)
BMI	Comparing BMI (kg/m^2) between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups	Baseline to Endpoint (3 Years)
eGFR	Comparing eGFR (ml/min1.73m^2) between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups	Baseline to Endpoint (3 Years)
Proportion of individuals with ≥ 50% decline in eGFR	Comparing the proportion of individuals with ≥ 50% decline in eGFR between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups	Baseline to Endpoint (3 Years)
uACR	Comparing uACR (mg/mmol) between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups	Baseline to Endpoint (3 Years)
ALT	Comparing ALT (U/L) between patients with T2D initiating semaglutide and patients with T2D initiating other AHAs among GLP-1-naïve versus GLP-1-experienced subgroups	Baseline to Endpoint (3 Years)

Collaborators and Investigators

• Sponsor: LMC Diabetes & Endocrinology Ltd.

Study record dates

Study Major Dates

• Study Start (Estimated): March 1, 2026
• Primary Completion (Estimated): April 1, 2026
• Study Completion (Estimated): May 1, 2026

Study Registration Dates

• First Submitted: February 13, 2026
• First Submitted That Met QC Criteria: February 13, 2026
• First Posted (Actual): February 20, 2026

Study Record Updates

• Last Update Posted (Actual): February 20, 2026
• Last Update Submitted That Met QC Criteria: February 13, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: HbA1c; semaglutide; T2D; AHA
• Additional Relevant MeSH Terms: Endocrine System Diseases; Nutrition Disorders; Metabolic Diseases; Overnutrition; Body Weight; Glucose Metabolism Disorders; Overweight; Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; Signs and Symptoms; Obesity; Diabetes Mellitus, Type 2; Diabetes Mellitus; semaglutide
• Other Study ID Numbers: SEMA-CKM

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: This is an observational study using data retrieved from a national diabetes registry. IPD will not be shared.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No